The US healthcare system is largely designed to treat people with acute problems. Whether it is a trip to the ER, a hospitalization or a clinic visit, the intervention is largely disease and symptom-focused. But for the most part, people – even those with chronic illness – live outside of the health care system. Because life happens outside of the clinician’s office, adherence (or non-adherence) to treatment plans happens here as well.
It’s where the daily llife’s context of patient behaviors occurs that determine health outcomes and health costs. It’s where people live, work and play to which Quvium’s tag line ‘Engaging Innovation’ speaks. The technology empowers and supports patients and their families’ ability to make daily decisions about their own health.
Of all the chronic diseases, Quvium can have the greatest impact on conditions where behavior modification and community engagement play a critical role in improving health outcomes and reducing acute care costs. Pediatric asthma, adult asthma, cardiometabolic syndrome and COPD are just a few of the seventy conditions and treatment categories where Quvium can offer an inimitable value proposition for payers, providers and patients.